AusperBio is a privately held biotech with operations in the United States and China that focuses on advancing oligonucleotide and targeted-delivery technologies. Its proprietary Med-Oligo™ ASO platform is designed to enhance antisense oligonucleotide therapeutics across viral, metabolic, genetic and immune diseases. The lead candidate, AHB-137, is a dual-mechanism, unconjugated ASO that has finished a global Phase I study and is now in multiple Phase II trials as well as a pivotal Phase III trial in China. Clinical data presented at major liver conferences (EASL, AASLD, APASL) have reinforced AHB-137’s potential as a backbone therapy for chronic hepatitis B. With the newly raised capital, AusperBio plans to accelerate pivotal development of AHB-137, launch additional Phase II combination studies, and expand global Phase II efforts. The funds will also support scaling commercial manufacturing partnerships and advance a broader preclinical pipeline. While revenue and user metrics are not disclosed, the company remains financed by a strong syndicate of life-science investors that have demonstrated continued confidence in its platform and development trajectory.

Total raised

$237M

Funding rounds

5

Latest round

Series B

Latest activity

Sep 2025